Ind-Swift Laboratories Ltd Share Price – NSE  /  BSE

Pharmaceuticals, Small Cap

Ind-Swift Laboratories announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 22 July 2024 .

Powered by Capital Market - Live News

Ind-Swift Laboratories will hold a meeting of the Board of Directors of the Company on 27 June 2024.

Powered by Capital Market - Live News

The key equity indices traded with minor gains in early trade. The Nifty traded above 23,550 mark. PSU Bank, media and consumer durables stocks advanced while realty and IT shares declined.

At 09:30 IST, the barometer index, the S&P BSE Sensex, was up 190.76 points or 0.25% to 77,531.84. The Nifty 50 index rose 39.85 points or 0.17% to 23,577.70.

The broader market outperformed the frontline indices. The S&P BSE Mid-Cap index rose 0.49% and the S&P BSE Small-Cap index added 0.81%.

The market breadth was strong. On the BSE, 2,256 shares rose and 662 shares fell. A total of 96 shares were unchanged.

Foreign portfolio investors (FPIs) sold shares worth Rs 653.97 crore, while domestic institutional investors (DIIs), were net sellers to the tune of Rs 820.47 crore in the Indian equity market on 24 June 2024, provisional data showed.

Economy:

India's telecom spectrum auction starts today (June 25th) offering airwaves worth Rs 96,318 crore. The government reportedly aims for Rs 10,000 crore. This auction includes frequencies from 800 MHz to 26 GHz bands and offers 20-year validity with options for sharing or surrendering spectrum after 10 years.

Stocks in Spotlight:

Ind-Swift Laboratories rallied 3.64% to Rs 122.50 after the company said that its board will meet on Thursday, 27 June 2024 to raise funds by issuing one or more instruments through various modes.

Satin Creditcare Network added 1.45% to Rs 237.75 after the company announced to raise up to Rs 5,000 crore through non-convertible debentures. The micro financier has also approved the appointment of its chief financial officer.

Sun Pharmaceuticals Industries rose 0.06% to Rs 1,495.70. The company successfully completed the merger of Taro Pharmaceutical Industries with its subsidiary company. As part of this merger, Sun Pharma acquired all outstanding ordinary shares of Taro other than those already held by Sun Pharma or its affiliates.

Numbers to Track:

The yield on India's 10-year benchmark federal rose 0.06% to 6.975 as compared with previous close 6.971.

In the foreign exchange market, the rupee edged higher against the dollar. The partially convertible rupee was hovering at 83.4700, compared with its close of 83.4775 during the previous trading session.

MCX Gold futures for 5 August 2024 settlement shed 0.16% to Rs 71,677.

The US Dollar index (DXY), which tracks the greenback's value against a basket of currencies, was down 0.03% to 105.44.

The United States 10-year bond yield declined 0.33% to 4.235.

In the commodities market, Brent crude for August 2024 settlement lost 5 cents or 0.06% to $85.96 a barrel.

Global Markets:

Asian shares traded higher on Tuesday, with investor eyes set on Friday's crucial U.S. inflation data. The upcoming U.S. presidential debate on Thursday and the first French election round this weekend are also adding to the cautious sentiment, as investors weigh potential political impacts on their holdings.

Wall Street closed with mixed results overnight. The Nasdaq suffered a significant drop of over 1%, led by a 7% plunge in AI leader Nvidia. This decline suggests investors are shifting out of technology stocks for now. However, the Dow Jones bucked the trend, climbing 0.7% to reach a one-month high. The S&P 500 ended slightly lower, down 0.31%.

Powered by Capital Market - Live News

The company’s board will meet to consider and approve the proposal for raising of funds by way of issuance of one or more instruments including equity shares/ convertible securities either by way of preferential issue/ rights issue/ QIP/ or any other mode as may be considered

Ind-Swift Laboratories is engaged in manufacturing pharmaceutical products especially active pharmaceutical ingredients (APIs) & advanced intermediates.

The company reported consolidated net profit of Rs 238.82 crore in Q4 FY24 as compared with net loss of Rs 25.12 crore in Q4 FY23. Revenue from operations jumped 29.3% YoY to Rs 393.33 crore in Q4 FY24.

The scrip rose 1.89% to settle at Rs 118.70 on Monday, 24 June 2024.

Powered by Capital Market - Live News